申请人长期从事干细胞与心肌修复的基础与转化研究，以项目负责人承担863项目1项、国家自然科学基金3项。在Circulation Research等杂志发表SCI论文30篇，其中第一（共同第一）或共同通讯作者12篇，他引558次。主要成果包括:（1）创新性提出低氧预处理能显著提高干细胞存活率和移植疗效，并建立了适用于临床的干细胞低氧预处理技术；（2）揭示了heparanase/intergrinβ1//HIF2α/ Flk-1/P38以及钾离子通道蛋白 Kv2.1在低氧处理增强 MSC的迁移和血管新生中起到重要作用，为干细胞迁移和血管新生提出了新的机制；（3）揭示了瘦素/瘦素受体介导的信号通路在低氧处理提高细胞存活能力方面起到重要作用，为提高干细胞存活率提出了新的靶点。本项目在前期工作基础上，主要研究细胞界面工程负载瘦素提高MSC移植疗效的作用及机制，为解决临床关键问题提供新的方法。

The applicant has been engaged in basic and translational research of stem cells and myocardial repair for more than 10 years. She is the principle investigator of 863 project from MOST and got the funding from 3 NSFC projects. So far, she has published 30 SCI papers in top journals such as Circulation Research, which has been cited for 558 times. The main achievements include: (1) first demonstrated hypoxic preconditioning can significantly improve the therapeutic efficacy of stem cell therapy and established hypoxia preconditioning technique for clinical stem cell therapy; (2) first demonstratedthe important role of heperanase/intergrin β1/HIF2α/Flk-1/p38 signal pathway and Kv2.1 in migration and angiogenesis of MSC,then provided the new insight of cell migration and angiogenesis;(3)demonstrated the effect of leptin/leptin receptor mediated signal pathway in MSC survival and provided the novel target for improving cell survival. Based on these previous work, we will develop a cell surface bioengineering methodology and modify the MSC with leptin, then to explore its effect and mechanism on myocardial repair. This project provides new ideas and methods to solve the key clinic questions through multidisciplinary efforts.